MTHFD1 Antibody

What is MTHFD1 and why is it important in biological research?

MTHFD1 is a trifunctional enzyme possessing three distinct enzymatic activities: methylenetetrahydrofolate dehydrogenase, methylenetetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetase. These activities make MTHFD1 a crucial component in one-carbon metabolism, providing activated C1 groups necessary for methionine, pyrimidine, and purine biosynthesis . MTHFD1 has gained research significance due to its involvement in several pathological conditions. Mutations in the MTHFD1 gene have been linked to severe megaloblastic anemia and combined immunodeficiency . Additionally, MTHFD1 has been identified as a host factor required for the replication of multiple RNA viruses and has been implicated in cancer progression, particularly in colorectal cancer (CRC) . The multifaceted role of MTHFD1 in cellular metabolism, disease pathogenesis, and viral replication makes it an important target for investigation using antibody-based detection methods.

How do MTHFD1 antibodies work in detecting the target protein?

MTHFD1 antibodies function through specific antigen-antibody interactions, recognizing unique epitopes on the MTHFD1 protein. When using these antibodies in research, they bind to their target with high specificity, allowing researchers to detect, quantify, or visualize MTHFD1 in biological samples. The antibody binding can be detected through various secondary detection systems, such as fluorescent tags, enzyme conjugates (HRP/AP), or colloidal gold, depending on the application. In Western blot applications, MTHFD1 antibodies enable detection of the protein after separation by electrophoresis, while in immunohistochemistry, they allow visualization of MTHFD1 expression patterns in tissue sections . These antibodies have been instrumental in studies demonstrating MTHFD1 overexpression in various cancer types and elucidating its role in viral replication . Researchers should verify the specificity of their MTHFD1 antibody by checking for single bands at the expected molecular weight (approximately 100 kDa) in Western blot analyses and conducting appropriate controls.

What are the common sources and types of MTHFD1 antibodies available for research?

MTHFD1 antibodies for research applications are primarily available as polyclonal and monoclonal varieties, each with distinct advantages for specific applications. Polyclonal antibodies, like the Proteintech 10794-1-AP anti-MTHFD1 antibody mentioned in the literature , recognize multiple epitopes on the MTHFD1 protein, often providing higher sensitivity but potentially lower specificity. Monoclonal antibodies, conversely, target single epitopes, offering higher specificity but sometimes reduced sensitivity. MTHFD1 antibodies are typically generated in various host species including rabbit, mouse, and goat, with rabbit-derived antibodies being common for their robust immune response and compatibility with many detection systems. These antibodies can be produced against different regions of the MTHFD1 protein, including the N-terminal domain containing dehydrogenase and cyclohydrolase activities or the C-terminal domain with formyl tetrahydrofolate synthetase activity . Research-grade MTHFD1 antibodies are available from multiple vendors, with validation data typically including Western blot results, immunohistochemistry images, and specificity testing.

How should MTHFD1 antibodies be optimized for Western blot analysis?

Optimizing MTHFD1 antibodies for Western blot analysis requires systematic adjustment of multiple parameters to achieve specific and sensitive detection. Begin with sample preparation by efficiently extracting MTHFD1 using an appropriate lysis buffer (RIPA or NP-40 based buffers with protease inhibitors) and determining protein concentration through Bradford or BCA assays. For MTHFD1 detection, load 20-30 μg of total protein and separate on a 7.5-10% SDS-PAGE gel, as MTHFD1 has a molecular weight of approximately 100 kDa .

During optimization, test different antibody dilutions (typically starting with 1:1000 and adjusting between 1:500-1:5000) based on signal strength and background levels. Incubation conditions may need adjustment - try overnight incubation at 4°C or 2-4 hours at room temperature. The blocking reagent (5% non-fat milk or BSA in TBST) should be optimized to minimize background signal. If detection sensitivity is an issue, consider longer exposure times or more sensitive detection systems like enhanced chemiluminescence (ECL).

To validate specificity, include positive controls (tissues or cell lines known to express MTHFD1, such as HCT-116 or DLD-1 colorectal cancer cell lines) and negative controls (MTHFD1 knockdown samples) . Researchers should expect a clean, single band at approximately 100 kDa when blotting for MTHFD1, as demonstrated in studies examining its expression in cancer cell lines .

What are the best practices for using MTHFD1 antibodies in immunohistochemistry (IHC)?

When using MTHFD1 antibodies for immunohistochemistry, several critical methodological considerations ensure optimal results. Tissue preparation is the first crucial step—samples should be properly fixed (typically with 10% neutral buffered formalin for 24-48 hours), processed, and sectioned at 4-5 μm thickness. Antigen retrieval is essential for MTHFD1 detection; heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes is generally effective in unmasking epitopes.

Optimization of antibody dilution is necessary, with initial testing recommended at the manufacturer's suggested range (typically 1:100-1:500 for MTHFD1 antibodies). The incubation time and temperature affect staining quality—overnight incubation at 4°C often provides the best balance of signal-to-noise ratio. For detection systems, researchers may choose between chromogenic methods (DAB/HRP) or fluorescent labeling depending on experimental requirements and available imaging systems.

Controls are indispensable: include positive control tissues known to express MTHFD1 (e.g., colorectal cancer tissues that overexpress MTHFD1) , negative controls (omitting primary antibody), and ideally, MTHFD1 knockdown tissues. Quantification of MTHFD1 expression should follow standardized scoring systems based on staining intensity and percentage of positive cells, as demonstrated in studies examining MTHFD1 expression in tumor versus normal tissues . This approach allows for reliable comparison of MTHFD1 expression across different experimental conditions or patient samples.

How can flow cytometry be optimized for MTHFD1 antibody-based detection?

Optimizing flow cytometry for MTHFD1 detection requires careful consideration of this protein's predominant intracellular localization. Since MTHFD1 is primarily cytosolic, cell fixation and permeabilization are essential steps. Begin with a single-cell suspension of approximately 1×10^6 cells per sample, then fix with 4% paraformaldehyde for 15 minutes at room temperature. For permeabilization, use either 0.1% Triton X-100, 0.1% saponin, or commercial permeabilization buffers, testing each to determine which provides optimal access to intracellular MTHFD1 while maintaining cellular integrity.

For antibody staining, titrate the MTHFD1 primary antibody to identify the optimal concentration that maximizes the positive signal while minimizing background fluorescence. Typically, starting dilutions range from 1:50 to 1:200 for direct conjugates or when using indirect detection methods. When using indirect detection, select a fluorochrome-conjugated secondary antibody that matches your flow cytometer's laser configuration and offers minimal spectral overlap with other fluorochromes in your panel.

Essential controls include: (1) unstained cells, (2) isotype controls matching the MTHFD1 antibody's host species and isotype, (3) fluorescence minus one (FMO) controls, and (4) positive controls using cell lines with known high MTHFD1 expression such as HCT-116 or DLD-1 . For validation, compare MTHFD1 detection in wild-type cells versus MTHFD1 knockdown cells to confirm specificity. During analysis, gate based on forward and side scatter to exclude debris and dead cells, and use compensation when multiple fluorochromes are employed to correct for spectral overlap.

What are common issues when using MTHFD1 antibodies and how can they be resolved?

Researchers commonly encounter several issues when working with MTHFD1 antibodies, each requiring specific troubleshooting approaches:

• Weak or absent signal in Western blots: This may result from insufficient protein loading, ineffective protein transfer, or suboptimal antibody concentration. Increase protein loading to 30-50 μg, optimize transfer conditions (potentially using lower methanol concentration in transfer buffer for high-molecular-weight MTHFD1), and test a range of primary antibody concentrations. Additionally, extending exposure time or using more sensitive detection systems may help.

• High background in immunohistochemistry: This often stems from insufficient blocking or excessive antibody concentration. Implement more stringent blocking (5% BSA or 10% normal serum from the secondary antibody's host species) for 1-2 hours at room temperature. Dilute the primary antibody further and reduce incubation temperature to 4°C. Multiple washing steps with agitation between antibody incubations significantly reduce background.

• Non-specific bands in Western blot: These might indicate antibody cross-reactivity or sample degradation. Verify antibody specificity using MTHFD1 knockdown samples as negative controls . Prepare fresh samples with complete protease inhibitor cocktails and maintain cold conditions throughout processing to prevent degradation.

• Inconsistent results between experiments: Standardize all protocols and reagents, including sample preparation methods, antibody lots, and incubation conditions. Prepare larger volumes of antibody dilutions for multi-experiment use, and include consistent positive controls in each experiment, such as lysates from HCT-116 cells known to express MTHFD1 .

• Poor signal in fixed tissues: MTHFD1 epitopes may be masked by fixation. Optimize antigen retrieval methods by testing different buffers (citrate pH 6.0 versus EDTA pH 9.0) and retrieval times. For particularly challenging samples, consider enzyme-based retrieval (proteinase K) or test different fixation protocols in future experiments.

How should researchers validate MTHFD1 antibody specificity?

Validating MTHFD1 antibody specificity requires a multi-faceted approach to ensure reliable research outcomes. The gold standard validation method involves comparing antibody signals between wild-type samples and those with genetic manipulation of MTHFD1. Researchers should generate MTHFD1 knockdown cells using siRNA, shRNA, or CRISPR-Cas9 technology, as demonstrated in studies using HCT-116 and DLD-1 cell lines . In Western blot analysis, a specific antibody should show significantly reduced or absent signal in knockdown samples compared to controls.

For additional validation, overexpression systems can be employed. Transfecting cells with MTHFD1 expression constructs should result in enhanced antibody signal compared to vector-only controls, as demonstrated in studies with DLD-1 and SW480 cells overexpressing MTHFD1 . Researchers should also conduct peptide competition assays, where pre-incubation of the antibody with the immunizing peptide should abolish specific signals if the antibody is truly specific.

Cross-validation using multiple antibodies targeting different MTHFD1 epitopes provides another layer of confidence. If multiple antibodies show concordant detection patterns across various techniques, specificity is more likely. Additionally, correlation of protein detection with mRNA expression data can further support antibody specificity. For instance, antibody-based protein detection should align with MTHFD1 mRNA levels observed in databases like TIMER, which showed elevated MTHFD1 expression in multiple cancer types compared to normal tissues .

What are the best sample preparation methods for MTHFD1 detection in different cellular fractions?

Detecting MTHFD1 in different cellular fractions requires tailored sample preparation methods that preserve protein integrity while enriching for specific cellular compartments. For total cell lysates, use a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and a complete protease inhibitor cocktail. Incubate cells for 30 minutes on ice with occasional vortexing, then centrifuge at 14,000 × g for 15 minutes at 4°C to remove debris.

For cytosolic fraction enrichment, which is particularly relevant for MTHFD1 given its primary cytosolic localization, use a hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, 0.5 mM DTT) with protease inhibitors. After swelling cells on ice for 15 minutes, add NP-40 to 0.6% final concentration, vortex briefly, and centrifuge at 10,000 × g for 10 minutes at 4°C. The supernatant contains the cytosolic fraction with enriched MTHFD1.

If investigating potential nuclear localization of MTHFD1, resuspend the nuclear pellet from cytosolic extraction in high-salt buffer (20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 25% glycerol) with protease inhibitors. Incubate with rotation for 30 minutes at 4°C, then centrifuge at 16,000 × g for 20 minutes.

For membrane fraction analysis, use a sucrose gradient separation after initial cell lysis. Protein concentration should be determined using Bradford or BCA assays for all fractions. Validation of fractionation quality should employ fraction-specific markers: β-actin for cytosolic fraction, GAPDH for cytosolic fraction, lamin A/C for nuclear fraction, and Na⁺/K⁺-ATPase for membrane fractions. Store all fractions at -80°C with 10% glycerol to maintain protein stability.

How can MTHFD1 antibodies be used to investigate its role in cancer progression?

MTHFD1 antibodies serve as powerful tools for investigating this enzyme's role in cancer progression through multiple advanced applications. Immunohistochemistry with MTHFD1 antibodies allows researchers to examine expression patterns across tumor stages and correlate with clinical outcomes. Studies have demonstrated that MTHFD1 is significantly overexpressed in colorectal cancer compared to normal tissues, with expression levels potentially serving as prognostic indicators . Researchers should employ standardized scoring systems when quantifying MTHFD1 expression in tissue microarrays containing samples from different cancer stages.

For functional studies, MTHFD1 antibodies can be combined with genetic manipulation approaches. After generating MTHFD1 knockdown or overexpression cancer cell lines, Western blot analysis using MTHFD1 antibodies confirms the altered expression levels before proceeding with functional assays. Such approaches have revealed that MTHFD1 overexpression enhances proliferation, migration, and invasion capabilities of colorectal cancer cells (DLD-1 and SW480), while knockdown suppresses these oncogenic properties in HCT-116 and DLD-1 cells .

Co-immunoprecipitation using MTHFD1 antibodies helps identify protein interaction partners in cancer cells, potentially revealing novel signaling networks. Additionally, chromatin immunoprecipitation (ChIP) can be used if MTHFD1 is suspected to interact with chromatin or function in epigenetic regulation. Immunofluorescence co-localization studies with MTHFD1 antibodies and markers of subcellular compartments or autophagy-related proteins can elucidate its spatial relationship with PI3K-AKT-mTOR signaling components, helping explain how MTHFD1 regulates autophagy to promote tumor growth .

What methods can be used to study MTHFD1's interaction with the PI3K-AKT-mTOR signaling pathway?

Investigating MTHFD1's interaction with the PI3K-AKT-mTOR signaling pathway requires sophisticated methodological approaches centered around MTHFD1 antibody applications. Co-immunoprecipitation (Co-IP) serves as a primary technique—researchers can use MTHFD1 antibodies conjugated to protein A/G beads to pull down MTHFD1 and its associated proteins from cell lysates, followed by Western blot analysis to detect components of the PI3K-AKT-mTOR pathway. The reverse approach, immunoprecipitating pathway components and probing for MTHFD1, can validate these interactions.

Proximity ligation assay (PLA) offers a powerful method to visualize protein-protein interactions in situ. By using primary antibodies against MTHFD1 and specific pathway components (like mTOR, Akt, or PI3K subunits), followed by species-specific secondary antibodies linked to oligonucleotides, researchers can detect interactions as fluorescent spots when proteins are within 40 nm of each other. This technique provides spatial information about where in the cell these interactions occur.

For functional studies, researchers should employ genetic manipulation of MTHFD1 (knockdown or overexpression) followed by Western blot analysis of phosphorylated and total forms of key pathway components. Studies have shown that modulating MTHFD1 expression affects autophagy protein levels and PI3K-AKT-mTOR signaling pathway expression in colorectal cancer cells . These experiments should include controls with pathway inhibitors (e.g., rapamycin for mTOR, LY294002 for PI3K) to validate specificity of the observed effects.

Time-course experiments after MTHFD1 manipulation can determine whether it acts upstream or downstream of specific pathway components. Advanced imaging approaches like FRET (Fluorescence Resonance Energy Transfer) using fluorescently labeled antibodies can further characterize the dynamics and proximity of these interactions in living cells.

How can MTHFD1 antibodies be utilized in viral infection research?

MTHFD1 antibodies offer significant utility in viral infection research, following the discovery that MTHFD1 serves as a key host factor for RNA virus replication. For monitoring MTHFD1 expression during viral infection, Western blot analysis using anti-MTHFD1 antibodies (such as Proteintech 10794-1-AP) enables quantification of expression levels in infected versus uninfected cells across different time points . This approach allows researchers to determine whether viruses modulate MTHFD1 expression as part of their replication strategy.

Immunofluorescence microscopy with MTHFD1 antibodies in virus-infected cells can reveal changes in subcellular localization or potential co-localization with viral proteins, providing insights into how viruses might recruit or interact with MTHFD1. This technique should be combined with antibodies against viral proteins, such as IAV M1 protein, to visualize spatial relationships .

For mechanistic studies, researchers can employ MTHFD1 antibodies in RNA immunoprecipitation (RIP) assays to investigate potential interactions between MTHFD1 and viral RNA. Additionally, proximity-based labeling approaches such as BioID or APEX2, where MTHFD1 is fused to a biotin ligase or peroxidase, followed by streptavidin pull-down and mass spectrometry, can identify the protein interactome of MTHFD1 during viral infection.

When evaluating antiviral compounds targeting MTHFD1, such as carolacton, MTHFD1 antibodies provide essential tools for target engagement studies. These could include cellular thermal shift assays (CETSA) or drug affinity responsive target stability (DARTS) approaches to confirm that the compounds are indeed binding to and affecting MTHFD1 in the cellular context of viral infection .

How should researchers quantify and normalize MTHFD1 expression data in different experimental contexts?

In immunohistochemistry quantification, multiple scoring systems can be applied: (1) the H-score method, which combines staining intensity (0-3) with percentage of positive cells, yielding scores from 0-300; (2) the Allred score, combining intensity and proportion scores; or (3) digital image analysis using specialized software for more objective quantification. For tissue microarrays, analyze multiple cores per sample to account for tumor heterogeneity, and have at least two independent observers score the samples to ensure reproducibility.

For qPCR analyses of MTHFD1 mRNA, normalization to multiple reference genes is recommended. Studies have used differential MTHFD1 mRNA expression between tumor and normal tissues from databases like TIMER to validate protein-level findings . When comparing MTHFD1 expression across different experimental conditions, such as in virus infection studies, consider using relative expression ratios rather than absolute values, and apply appropriate statistical tests for group comparisons (paired t-tests for matched samples, ANOVA for multiple group comparisons).

What are the considerations for interpreting MTHFD1 expression changes in disease states?

Interpreting MTHFD1 expression changes in disease states requires careful consideration of multiple factors to avoid misattribution or oversimplification. Researchers should first establish baseline MTHFD1 expression in relevant normal tissues or cell types, as expression levels naturally vary across different tissues and cell types. This baseline provides the necessary context for interpreting disease-associated changes. In cancer studies, MTHFD1 has been found significantly overexpressed in multiple cancer types including bladder, colorectal, esophageal, head and neck, lung, prostate, gastric, and endometrial cancers compared to corresponding normal tissues .

The heterogeneity of MTHFD1 expression within disease samples must be acknowledged. In tumor samples, expression may vary across different regions or cell populations, necessitating analysis of multiple samples or regions. When possible, correlate MTHFD1 expression with specific histopathological features or molecular subtypes of the disease to identify particular contexts where MTHFD1 alterations are most relevant.

Consider the functional significance of observed expression changes by integrating data on MTHFD1 enzymatic activities. Since MTHFD1 possesses three distinct enzymatic functions (dehydrogenase, cyclohydrolase, and synthetase activities), changes in expression might differentially affect these activities, particularly if mutations are present . Researchers should also assess whether observed changes in MTHFD1 protein levels correlate with alterations in one-carbon metabolism products or folate cycle intermediates.

For clinical relevance, correlate MTHFD1 expression with disease progression markers, patient survival, or treatment response. Studies have shown that high MTHFD1 expression in hepatocellular carcinoma was independently associated with worse prognosis , suggesting potential prognostic value. Finally, consider whether MTHFD1 alterations are causal factors or consequences of the disease state by employing experimental manipulation in appropriate model systems.

How can researchers distinguish between the different enzymatic functions of MTHFD1 using antibody-based approaches?

Distinguishing between MTHFD1's three enzymatic functions (methylenetetrahydrofolate dehydrogenase, methylenetetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetase) using antibody-based approaches presents a sophisticated challenge requiring specialized techniques. Domain-specific antibodies offer the most direct approach—researchers should utilize antibodies targeting distinct domains of MTHFD1: the N-terminal domain containing dehydrogenase and cyclohydrolase activities, and the C-terminal domain with formyl tetrahydrofolate synthetase activity . Western blot analysis with these domain-specific antibodies can reveal selective changes in expression or post-translational modifications of particular domains.

Activity-state specific antibodies, though challenging to develop, can be powerful tools if available. These antibodies recognize conformational epitopes present only when the enzyme adopts certain catalytically active or inactive states. Phospho-specific antibodies may help if enzymatic activities are regulated by phosphorylation events. After immunoprecipitation with general MTHFD1 antibodies, researchers can probe with phospho-specific antibodies to correlate phosphorylation status with specific enzymatic activities.

Functional correlation studies provide indirect evidence—researchers can perform enzyme activity assays after immunoprecipitation with MTHFD1 antibodies from cellular extracts under different experimental conditions. By correlating changes in specific enzymatic activities with antibody-detected expression patterns or modifications, researchers can infer relationships between detected protein states and functions. For instance, studies have shown that the formyl tetrahydrofolate synthetase activity of MTHFD1 is essential for RNA virus replication, as this function affects cellular purine levels that can be rescued by supplementation with purine analogs like hypoxanthine or inosine .

How can MTHFD1 antibodies be integrated into multiplexed imaging approaches?

Integrating MTHFD1 antibodies into multiplexed imaging approaches enables simultaneous visualization of MTHFD1 alongside multiple markers, providing comprehensive spatial context in complex biological systems. For multiplexed immunofluorescence, researchers should optimize MTHFD1 antibody concentration, incubation conditions, and fluorophore selection to ensure compatibility with other antibodies in the panel. Tyramide signal amplification (TSA) can significantly enhance detection sensitivity for MTHFD1, allowing for use of more dilute antibody concentrations that minimize cross-reactivity. When designing panels, pair MTHFD1 antibodies with markers of cellular compartments, signaling pathway components (PI3K, AKT, mTOR), or autophagy markers to investigate functional relationships .

Mass cytometry-based imaging approaches like Imaging Mass Cytometry (IMC) or Multiplexed Ion Beam Imaging (MIBI) offer exceptional multiplexing capacity. For these platforms, MTHFD1 antibodies must be conjugated to isotope-pure metal tags, typically through polymer-based methods or direct conjugation. These techniques allow simultaneous visualization of MTHFD1 with 40+ other markers without spectral overlap concerns. Researchers should validate metal-conjugated MTHFD1 antibodies against conventional immunohistochemistry results before proceeding with multiplexed analysis.

For cyclic immunofluorescence methods (CyCIF, 4i, or CODEX), where antibodies are iteratively applied, stripped, and reapplied, determine the optimal cycle for MTHFD1 detection based on epitope sensitivity to stripping procedures. Signal-to-noise ratio may be optimized by placing MTHFD1 detection in earlier cycles if the epitope is sensitive to multiple stripping rounds. These approaches have particular value in studying MTHFD1's relationship to cancer progression and viral infection processes, allowing researchers to map MTHFD1 expression patterns in the context of tumor microenvironments or virus-infected tissue architecture.

What approaches can be used to study post-translational modifications of MTHFD1 using antibodies?

Studying post-translational modifications (PTMs) of MTHFD1 requires sophisticated antibody-based approaches to capture these often transient but functionally significant protein states. Modification-specific antibodies represent the most direct approach—researchers should utilize antibodies specifically recognizing phosphorylated, acetylated, methylated, or ubiquitinated forms of MTHFD1. While commercial availability of such antibodies may be limited, custom antibody development against predicted or experimentally identified modified peptides is a viable strategy. When designing these antibodies, focus on sequences surrounding known or predicted modification sites, particularly those conserved across species.

For phosphorylation studies, researchers can employ a two-step immunoprecipitation approach: first, immunoprecipitate total MTHFD1 using general antibodies, then probe with pan-phospho-antibodies (anti-phospho-serine/threonine/tyrosine). Alternatively, immunoprecipitate with phospho-specific antibodies and probe with general MTHFD1 antibodies. This approach can reveal whether MTHFD1 phosphorylation status changes under different conditions, such as viral infection or cancer progression .

Mass spectrometry following immunoprecipitation provides comprehensive PTM profiling. After immunoprecipitating MTHFD1 using validated antibodies, perform mass spectrometry analysis to identify and quantify multiple PTMs simultaneously. This approach can uncover novel modifications and their stoichiometry. Additionally, proximity ligation assays can detect interactions between MTHFD1 and modifying enzymes (kinases, acetylases, etc.) within cells, providing spatial information about where modifications might occur.

For functional studies, correlate detected PTMs with MTHFD1's enzymatic activities by performing activity assays on immunoprecipitated protein fractions enriched for specific modifications. This approach can reveal how particular modifications affect MTHFD1's three distinct enzymatic functions, potentially explaining differential effects observed in disease states .

How can researchers use MTHFD1 antibodies to investigate its role in antiviral drug development?

MTHFD1 antibodies provide essential tools for antiviral drug development targeting this newly identified host factor for viral replication. Target validation studies represent a critical first application—researchers should use MTHFD1 antibodies in Western blot and immunofluorescence assays to confirm knockdown or overexpression efficiency in cell lines before assessing viral replication phenotypes. This approach has validated MTHFD1 as a required host factor for multiple RNA viruses, including influenza A virus (IAV), mumps virus (MuV), Melaka virus, Zika virus (ZIKV), and SARS-CoV-2 .

For mechanism of action studies of potential inhibitors like carolacton, MTHFD1 antibodies can be employed in cellular thermal shift assays (CETSA), where cells are treated with the compound, heated to various temperatures, and lysed. MTHFD1 antibodies then detect the remaining soluble protein via Western blot, with shifts in thermal stability indicating direct binding of the inhibitor to MTHFD1. Similarly, drug affinity responsive target stability (DARTS) assays use MTHFD1 antibodies to detect protection from protease digestion when the target is bound by inhibitors.

Pharmacodynamic biomarker development represents another application—MTHFD1 antibodies can monitor target engagement in treated cells or tissues through changes in expression, localization, or post-translational modifications. This approach helps establish dosing regimens that achieve sufficient target modulation. Additionally, immunohistochemistry with MTHFD1 antibodies in tissue samples from animal models can assess tissue distribution of target engagement across different organs.

For resistance mechanism studies, researchers can investigate whether viruses develop resistance to MTHFD1-targeting compounds through mutations in viral proteins or alterations in cellular pathways. MTHFD1 antibodies help monitor whether resistant viruses induce changes in MTHFD1 expression, localization, or interaction partners as adaptation mechanisms .